Fortress Biotech, Partex enter collaboration for asset identification, evaluatio

Partex NV and Fortress Biotech (FBIO) announced a strategic collaboration aimed at identifying and evaluating biopharmaceutical compounds using artificial intelligence for potential acquisition or licensing by Fortress. Partex will deploy its proprietary AI-based drug discovery and development technology platform, which delivers diverse recommendations on alternative targets or indications and helps search and evaluate compounds across therapeutic areas. Partex’s platform will provide comprehensive analyses, including target identification, indication expansion, and molecular profiling, ultimately accelerating the process of bringing innovative therapeutics faster to market.